These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25846055)

  • 1. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.
    Israeli E; Goldin E; Fishman S; Konikoff F; Lavy A; Chowers Y; Melzer E; Lahat A; Mahamid M; Shirin H; Nussinson E; Segol O; Ya'acov AB; Shabbat Y; Ilan Y
    Clin Exp Immunol; 2015 Aug; 181(2):362-72. PubMed ID: 25846055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
    Kim PS; Zlatanic J; Korelitz BI; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azathioprine: state of the art in inflammatory bowel disease.
    Sandborn WJ
    Scand J Gastroenterol Suppl; 1998; 225():92-9. PubMed ID: 9515759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
    Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
    Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.
    Prantera C; Lochs H; Grimaldi M; Danese S; Scribano ML; Gionchetti P;
    Gastroenterology; 2012 Mar; 142(3):473-481.e4. PubMed ID: 22155172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial.
    Israeli E; Zigmond E; Lalazar G; Klein A; Hemed N; Goldin E; Ilan Y
    World J Gastroenterol; 2015 May; 21(18):5685-94. PubMed ID: 25987796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: a multicentre, double-blind, randomized, parallel-group Phase II study.
    Suzuki Y; Motoya S; Takazoe M; Kosaka T; Date M; Nii M; Hibi T
    J Crohns Colitis; 2013 Apr; 7(3):239-47. PubMed ID: 22766525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
    Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
    Egan LJ; Sandborn WJ; Tremaine WJ
    Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
    N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach.
    Margalit M; Israeli E; Shibolet O; Zigmond E; Klein A; Hemed N; Donegan JJ; Rabbani E; Goldin E; Ilan Y
    Am J Gastroenterol; 2006 Mar; 101(3):561-8. PubMed ID: 16542292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
    Sandborn WJ; Lee SD; Tarabar D; Louis E; Klopocka M; Klaus J; Reinisch W; Hébuterne X; Park DI; Schreiber S; Nayak S; Ahmad A; Banerjee A; Brown LS; Cataldi F; Gorelick KJ; Cheng JB; Hassan-Zahraee M; Clare R; D'Haens GR
    Gut; 2018 Oct; 67(10):1824-1835. PubMed ID: 28982740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
    Dotan I; Rachmilewitz D; Schreiber S; Eliakim R; van der Woude CJ; Kornbluth A; Buchman AL; Bar-Meir S; Bokemeyer B; Goldin E; Maaser C; Mahadevan U; Seidler U; Hoffman JC; Homoky D; Plasse T; Powers B; Rutgeerts P; Hommes D;
    Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
    Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
    J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.
    Eser A; Colombel JF; Rutgeerts P; Vermeire S; Vogelsang H; Braddock M; Persson T; Reinisch W
    Inflamm Bowel Dis; 2015 Oct; 21(10):2247-53. PubMed ID: 26197451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
    N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial.
    de Groof EJ; Buskens CJ; Ponsioen CY; Dijkgraaf MG; D'Haens GR; Srivastava N; van Acker GJ; Jansen JM; Gerhards MF; Dijkstra G; Lange JF; Witteman BJ; Kruyt PM; Pronk A; van Tuyl SA; Bodelier A; Crolla RM; West RL; Vrijland WW; Consten EC; Brink MA; Tuynman JB; de Boer NK; Breukink SO; Pierik MJ; Oldenburg B; van der Meulen AE; Bonsing BA; Spinelli A; Danese S; Sacchi M; Warusavitarne J; Hart A; Yassin NA; Kennelly RP; Cullen GJ; Winter DC; Hawthorne AB; Torkington J; Bemelman WA
    Trials; 2015 Aug; 16():366. PubMed ID: 26289163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
    Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
    Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
    Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.